Method of treating cancer with anti-neurotrophin agents
CA 2401604 C · Owner: Cephalon, Inc. · Inventors: Miknyoczki, Sheila J.; Buchkovich, Karen J.; Ruggeri, Bruce A.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A method of treating or preventing cancer by administering to a mammal a therapeutically effective amount of at least one anti-neurotrophin agent is described. The anti-neurotrophin agent is preferably an anti-neurotrophin antibody, an antisense molecule directed to a neurotrophin a small organic , molecule which binds a neurotrophin or a dominant-negative mutation of a trk receptor that binds a neurotrophin. This method is particularly preferred for the treatment of prostate or pancreatic cancer. The anti-neurotrophic agents neutralize NGF, BDNF, NT-3, NT-4/5, NT-6 or NT-7 and include humanized antibodies as well as fragments thereof.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed February 28, 2001 and granted May 24, 2011. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended February 28, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by February 28, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.